Stem Cells for Stroke Recovery: What a Major Clinical Trial Found

A major clinical trial tested stem cells in 104 stroke patients and confirmed intravenous safety. Learn what the research found and what it means for future treatment.What Is a Stroke and Why Is It So Hard to Treat?

Every year, millions of people suffer a stroke — and many are left with permanent disabilities that conventional medicine cannot fully reverse. Could stem cells offer a new path forward? A major clinical trial involving 104 patients has provided some encouraging early answers, particularly around safety.

What Is a Stroke and Why Is It So Hard to Treat?

A stroke happens when blood flow to the brain is suddenly blocked. Without oxygen and nutrients, brain cells begin to die within minutes. The faster treatment begins, the better — but even with quick action, many survivors are left with long-term problems such as difficulty walking, speaking, or moving one side of their body.

Current treatments — including clot-dissolving drugs, medication, physiotherapy, and acupuncture — can help, but they have a significant limitation: dead brain cells cannot grow back. Once neurons are lost, conventional medicine has no reliable way to replace them. This is why researchers have been looking at stem cells as a potential new approach.

How Could Stem Cells Help After a Stroke?

Stem cells do not work by simply replacing lost brain cells. Instead, they appear to support the brain’s own recovery process in several important ways.

The type of stem cells studied most in stroke research are called mesenchymal stem cells (MSCs). When introduced into the body, these cells release signalling molecules that help reduce inflammation, protect surviving brain cells, encourage the growth of new blood vessels, and promote tissue repair.

They also stimulate the production of key growth factors — including BDNF, VEGF, and GDNF — that support the survival and function of neurons in the damaged area. Think of it less as rebuilding the brain directly, and more as creating a more favourable environment for the brain to heal itself.

The TREASURE Trial: What Was It?

One of the most well-structured studies in this area is the TREASURE trial — a Phase 2/3 randomised controlled trial published in JAMA Neurology, one of the world’s leading medical journals. It was led by researchers at Hokkaido University in Japan and conducted across 44 hospitals and clinical centres nationwide.

The trial enrolled 206 patients who had recently experienced an acute ischemic stroke. Half of them (104 patients) received stem cell therapy. The other half (102 patients) received a placebo — an inactive treatment that looked identical. Neither the patients nor the doctors assessing them knew who received which treatment, making the results as objective as possible.

Each patient in the treatment group received 1.2 billion allogeneic stem cells delivered intravenously — meaning through a drip into the bloodstream — within 18 to 36 hours of their stroke. “Allogeneic” simply means the cells came from a donor rather than the patient themselves, which makes it practical to prepare and use quickly in an emergency setting.

What Did the Trial Find?

Safety Was Confirmed

The most significant finding was on safety. Across all 104 patients who received the stem cell infusion, no serious adverse events were recorded. This is an important result because one of the biggest concerns with intravenous cell therapies has always been whether they are safe enough to use in acutely ill patients. This trial directly addressed that concern — and the answer was reassuring.

Efficacy Remains Under Investigation

When it came to measuring recovery outcomes at 90 days after treatment, the difference between the stem cell group and the placebo group was not statistically significant. In plain terms: the trial did not conclusively prove that the stem cell therapy improved patient outcomes compared to placebo.

However, this does not mean the therapy does not work. Clinical trials at this stage are designed to assess safety first, and the number of participants — while substantial — may not have been large enough to detect smaller but meaningful differences in outcomes. The researchers noted that certain patient groups may still benefit, and that further investigation is needed.

Why Does This Trial Matter?

This kind of rigorous, blinded, placebo-controlled trial is exactly what regulators and the medical community require before a new therapy can be widely considered. The TREASURE trial’s confirmation of safety in the acute post-stroke window is a necessary and meaningful milestone — without it, larger efficacy trials simply cannot move forward.

It also sits within a much larger global effort. At the time of the trial’s reporting, at least 65 clinical trials examining stem cell therapies for ischemic stroke were active or planned worldwide, with research underway in Japan, the United States, China, and beyond. Regulatory bodies including the US FDA, the European Medicines Agency (EMA), and Japan’s PMDA all maintain structured frameworks to guide this type of research safely.

What Happens Next?

Researchers are now focused on answering the questions this trial raised: Which patients are most likely to benefit? Is the current dose and timing optimal? What do long-term outcomes — beyond 90 days — look like?

As stem cell science advances and more data accumulates, the picture will become clearer. For now, stem cell therapy for ischemic stroke remains a promising area of ongoing research, not yet a standard treatment — but one that is progressing through the proper scientific and regulatory channels with growing evidence behind it.